ROIV · Roivant Sciences Ltd.
$40.82
-0.29% last session
End-of-day data · close of 2026-09-11
Market cap
$29B
Enterprise value
$26B
Trailing P/E
—
Forward P/E
-23.8
Dividend yield
—
Beta
1.12
Avg volume
7M
Employees
1K
Daily Change %
-0.29%
5 Days Change
17.21%
10 Days Change
18.60%
30 Days Change
13.22%
60 Days Change
18.63%
Month to Day Change
18.60%
Year to Day Change
88.66%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ROIV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Jefferies
Buy$52.00
+27.0% vs priceCitigroup
Buy$46.00
+12.4% vs priceGoldman Sachs
Buy$33.00
-19.4% vs priceJP Morgan
Overweight$20.00
-51.1% vs priceBank of America
Neutral$16.50
-59.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | TD Cowen | Maintains | Buy | $50.00 → $55.00 |
| 2026-09-09 | Guggenheim | Maintains | Buy | $42.00 → $46.00 |
| 2026-09-08 | HC Wainwright & Co. | Maintains | Buy | $41.00 → $47.00 |
| 2026-09-08 | Jefferies | Maintains | Buy | $42.00 → $52.00 |
| 2026-08-28 | HC Wainwright & Co. | Reiterates | Buy | $41.00 |
| 2026-08-10 | Citigroup | Maintains | Buy | $42.00 → $46.00 |
| 2026-08-07 | Guggenheim | Maintains | Buy | $36.00 → $42.00 |
| 2026-08-07 | HC Wainwright & Co. | Maintains | Buy | $34.00 → $41.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 68 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 14.1% above the 50-day MA ($35.79).
- Price vs 200-day MA: Trading 41.2% above the 200-day MA ($28.91).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.58) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($41.81).
ROIV Price Chart
Loading chart for ROIV…
Fundamentals
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 13.5% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$80B 3.2% YTD
ARGX
argenx SE
$62B 17.0% YTD
MRNA
Moderna, Inc.
$57B 363.3% YTD
RVMD
Revolution Medicines, Inc.
$44B 155.3% YTD
ONC
BeOne Medicines Ltd.
$39B 12.5% YTD
RPRX
Royalty Pharma plc
$34B 54.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -37.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.